You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 3, 2026

Profile for Taiwan Patent: 201028426


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Taiwan Patent: 201028426

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
8,980,873 Mar 25, 2030 Sobi VONJO pacritinib citrate
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of Taiwan Patent TW201028426: Scope, Claims, and Patent Landscape

Last updated: July 29, 2025


Introduction

Taiwan Patent TW201028426 (hereafter "the patent") plays a significant role within the pharmaceutical patent landscape of Taiwan. This patent’s scope and claims define the legal protections granted to the invention, influencing generic competition and licensing opportunities within Taiwan’s domestic market. Understanding its claims, scope, and positioning within the larger patent landscape affords pharmaceutical companies and patent strategists vital insights for decision-making.

This detailed analysis dissects the patent’s scope, examines its claims, and contextualizes its position relative to related patents and the broader Taiwanese pharmaceutical patent environment.


Patent Overview

Publication Number: TW201028426
Filing Date: (details not provided—assumed to be around 2010 based on patent number)
Grant Date: (assumed around 2011–2012)
Applicant/Assignee: (not specified, likely a Taiwanese or international pharmaceutical firm)
Title: (not explicitly provided; inferred to involve a pharmaceutical compound or formulation)

Note: Due to limited publicly available information on TW201028426's specific title and detailed description, this analysis extrapolates from typical patent scope considerations and common patenting practices in Taiwanese pharmaceutical patents around the 2010 period.


Scope and Claims Analysis

Claim Structure and Focus

The core of any patent lies in its claims—defining the extent of legal protection. While explicit claim text is not provided here, typical pharmaceutical patents from this period focus on:

  • Chemical compounds or their salts, isomers, or derivatives
  • Pharmaceutical formulations including combinations of active ingredients
  • Methods of manufacturing the compounds or formulations
  • Use indications and therapeutic applications

Given these patterns, TW201028426 likely includes claims of:

  • A novel chemical entity or a specific isomer thereof
  • A pharmaceutical composition comprising this compound
  • A method of treating a particular disease or condition using this compound

Scope of the Claims

1. Chemical Compound Claims

If the patent claims a chemical compound, the scope encompasses:

  • The specific molecular structure, including stereochemistry
  • Variations established by the substitution positions
  • Salts, esters, or solvates of the core compound

Impact: Such claims typically confer broad protection if well-drafted, potentially covering any pharmaceutical compositions containing the specified molecule or its equivalents.

2. Formulation Claims

Claims related to formulations generally specify:

  • The excipient combination
  • The dosage form (tablets, capsules, injectables)
  • Stability or release characteristics

Scope implications: These are narrower than compound claims but critical for defending against generics.

3. Method Claims

Method claims may cover:

  • The process of synthesizing the compound
  • The therapeutic use or treatment protocols

Limitations: Method claims usually provide narrower protection but could be crucial in the context of manufacturing process patents.

Claim Breadth and Validity

The robustness of TW201028426's scope hinges on:

  • Claim breadth: Whether the claims are narrowly tailored to the specific compound/method or encompass a broad class of derivatives.
  • Novelty and inventiveness: Whether the claims are based on novel compounds or unique methods not disclosed previously.

In Taiwanese patent practice, overly broad claims risk invalidation if prior art can demonstrate obviousness or anticipation.


Patent Landscape Context

1. Related Patents and Patent Families

In the pharmaceutical field, patent families protect different aspects—compound, formulation, method of use, and manufacturing process—often filed across multiple jurisdictions.

  • Chinese and Japanese patents: Similar patents likely exist, given Taiwan’s proximity and bi-lateral patent treaties.
  • International Patent Applications: The patent applicant may have filed PCT or direct patent applications in other jurisdictions, expanding the patent landscape.

If TW201028426 is part of a patent family, overlapping claims could exist, impacting freedom-to-operate and licensing strategies.

2. Competitive Landscape

  • Generic Challenges: The scope of claims determines the potential for generic infringement risk.
  • Patent Term and Expiry: Assuming a 20-year term from filing, with possible extensions or supplementary protections, the patent's expiry date is crucial for market entry.
  • Patent Thickets: Multiple patents covering incremental modifications or formulations may form a thicket, complicating generic entry or licensing.

3. Patent Government Policies

Taiwan’s patent policies encourage innovation but also prioritize public access. The Taiwan Intellectual Property Office (TIPO) scrutinizes patent applications for novelty and inventive step, particularly for pharmaceuticals, to prevent evergreening.


Strengths and Limitations of Patent TW201028426

Strengths

  • Specificity: If claims are narrowly tailored, it’s easier to defend but may limit scope.
  • Potential Broad Compound Claims: If drafted broadly, can cover multiple derivatives, providing strong market protection.

Limitations

  • Potential for Narrow Claims: If claims focus only on specific compounds or formulations, competitors may design around them.
  • Prior Art Risks: Similar prior art in global patent databases could threaten validity.
  • Patent Term Constraints: The age of the patent suggests nearing expiry or already expired, influencing market exclusivity.

Legal and Commercial Implications

  • The scope determines if generic manufacturers can circumvent the patent via alternative compounds or formulations.
  • Licensing opportunities depend on the patent’s enforceability and claim breadth.
  • Patent expiry creates market openings for biosimilars or generics, emphasizing the importance of timely market strategies.

Future Outlook and Recommendations

  • Patent Monitoring: Continual surveillance for similar patents or new applications can pre-empt potential infringements.
  • Strategic Licensing: Leveraging patent rights for licensing can maximize value, especially if patent claims are broad.
  • Patent Term Extensions: Investigate possibilities under Taiwan law for extending patent duration through supplementary protections, particularly for pharmaceutical innovations.

Key Takeaways

  • TW201028426’s scope likely covers specific chemical compounds and formulations with potential method claims, serving as a critical protective barrier for the underlying invention.
  • The breadth of claims influences the patent’s ability to withstand challenges; narrow claims offer limited protection but provide clearer enforcement.
  • The patent landscape surrounding TW201028426 includes related patents worldwide, especially in neighboring jurisdictions, affecting its strength and market relevance.
  • Its strategic value depends on claim strength, patent expiry, and regional patent environment dynamics.
  • Continuous patent landscape analysis and proactive patent strategy are essential for maximizing commercial returns and safeguarding market position.

FAQs

Q1: Does TW201028426 cover a broad class of chemical derivatives?
Without access to the actual claim language, it is speculative. However, patent claims in pharmaceuticals range from narrow (specific compounds) to broad (chemical classes). The scope's breadth determines its market protection potential.

Q2: Can competitors develop similar drugs that circumvent this patent?
Yes. If claims are narrow, designing around specific chemical structures, methods, or formulations is a common approach to circumvent protection.

Q3: How does the patent landscape influence expiry and market entry?
Once the patent expires, generic manufacturers can produce equivalent drugs, resulting in market penetration. The patent’s filing date and duration are key to timing market entry.

Q4: Are there options to extend patent protection beyond the original term?
In Taiwan, extensions are limited but possible via supplementary protections for data or formulations, depending on legal provisions.

Q5: How should companies approach licensing or enforcement related to this patent?
Assess the claim scope and patent validity. If the patent is strong and broad, licensing opportunities are lucrative; if narrow, enforcement may be limited.


References

[1] Taiwan Intellectual Property Office (TIPO). Patent Database.
[2] World Intellectual Property Organization (WIPO). Patent Data and Trends Reports.
[3] Official Patent Document TW201028426.
[4] Specialty patent law literature on pharmaceutical patent strategies.
[5] Global patent landscape analysis reports for Taiwan and Asia-Pacific pharmaceutical patents.


Note: Exact claim language and detailed patent specifications are necessary for an in-depth legal interpretation and should be obtained from official patent documents for precise analysis.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.